Sugi Predict

Sugi Predict / Compounds / SCHEMBL2914092

SCHEMBL2914092

SCHEMBL2914092

Cc1cscc1-c1cc(N2CCN(C)CC2)ccc1C(N)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ PTK2B Q14289 1/20 0.43
▸ PARP1 P09874 1/20 0.42
▸ JAK2 O60674 3/20 0.42
▸ JAK1 P23458 2/20 0.42
▸ TYK2 P29597 2/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ TACR1 P25103 1/20 0.42
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ TGFBR1 P36897 1/20 0.40
▸ ACVR1 Q04771 1/20 0.40
▸ NEK2 P51955 1/20 0.39
▸ CSF1R P07333 3/20 0.39
▸ LRRK2 Q5S007 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2913153 0.84 TACR1 (0.57) PARP1JAK2JAK1TYK2JAK3
SCHEMBL2915570 0.82 CSF1R (0.52) KDM4EGAAMAPTMAPK1HTT
SCHEMBL2907565 0.81 CSF1R (0.52) KDM4EGAAMAPTMAPK1HTT
SCHEMBL3230847 0.81 PARP1 (0.49) KDM4EGAAMAPTMAPK1HTT
SCHEMBL2907550 0.80 GAA (0.59) KDM4EGAAMAPTMAPK1HTT
SCHEMBL30760533 0.78 KMT2A (0.52) KDM4EGAAMAPTMAPK1HTT
SCHEMBL3224987 0.78 KMT2A (0.52) KDM4EGAAMAPTMAPK1HTT
SCHEMBL27997684 0.78 PARP1 (0.51) KDM4EGAAMAPTMAPK1HTT
SCHEMBL2943139 0.78 CSF1R (0.52) PARP1JAK2JAK1TYK2JAK3
Hydrochloric Acid SCHEMBL30760636 0.77 KMT2A (0.51) KDM4EGAAMAPTMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101340909-B Method of inhibiting flt3 kinase JANSSEN PHARMACEUTICA NV 2012-01-11 — — CN claimed
CN-101340909-A Method of inhibiting flt3 kinase JANSSEN PHARMACEUTICA NV (BE) 2009-01-07 — — CN claimed
EP-1951234-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-06 — — EP claimed
WO-2007048088-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-26 — — WO claimed
US-9526731-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2016-12-27 — — US disclosed
EP-1807077-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-11-23 — — EP disclosed
US-20150094520-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2015-04-02 — — US disclosed
US-8933091-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2015-01-13 — — US disclosed
US-8697716-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2014-04-15 — — US disclosed
US-20140005225-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-01-02 — — US disclosed
EP-2397138-B1 Aromatic amide derivatives as C-KIT kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-12-11 — — EP disclosed
US-8557847-B2 Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor JANSSEN PHARMACEUTICA, N.V. (BE) 2013-10-15 — — US disclosed
EP-1807077-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 — — EP disclosed
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-28 — — US disclosed
WO-2007048088-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-26 — — WO disclosed
WO-2006138155-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-28 — — WO disclosed
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 — — US disclosed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 — — US disclosed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 — — US disclosed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189623-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES KDM4E 2513/4885GAA 3385/4885MAPT 147/4885
US-20140005225-A1 METHOD OF INHIBITING C-KIT KINASE KIT, CHUK, MAP3K13 KDM4E 1145/4885GAA 969/4885MAPT 257/4885
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR FLT3, MCL1, CSF1R KDM4E 3127/4885GAA 977/4885MAPT 4541/4885
US-20060148812-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES KDM4E 2513/4885GAA 3385/4885MAPT 147/4885
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE FLT3, PLK1, PHKG1 KDM4E 3700/4885GAA 1634/4885MAPT 850/4885
US-20150094520-A1 METHOD OF INHIBITING C-KIT KINASE KIT, CHUK, MAP3K13 KDM4E 1145/4885GAA 969/4885MAPT 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.